GlassScriptPhysician profile
Colleen Cavanagh
NPI 1932748621
$5,662.85
in general payments reported to CMS, 2019-2025
31 companies · $168 in 2025
The $168 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,342 · 2022: $1,962 · 2023: $957 · 2024: $234 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,359.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,294.87 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $677.35 | 2021-2023 | Abilify Mycite, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $635.70 | 2021-2023 | Caplyta |
| Supernus Pharmaceuticals, INC. | $541.67 | 2021-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $504.07 | 2021-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $341.64 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $185.39 | 2021-2022 | |
| Neos Therapeutics, LP | $177.16 | 2021-2023 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Alkermes, INC. | $160.48 | 2021-2023 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $146.33 | 2022-2023 | Spravato |
| Tris Pharma INC | $144.07 | 2022-2023 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $122.45 | 2021-2024 | Belsomra, Gardasil, Proquad |
| Teva Pharmaceuticals USA, INC. | $111.89 | 2021 | |
| Sanofi-Aventis U.S. LLC | $68.75 | 2024-2025 | |
| Sanofi Pasteur INC. | $64.43 | 2023-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $58.99 | 2021 | |
| Idorsia Pharmaceuticals US INC | $52.55 | 2022-2023 | Quviviq |
| Neurocrine Biosciences, INC. | $50.22 | 2023 | Ingrezza |
| Eisai INC. | $44.06 | 2022 | |
| Seqirus USA INC | $37.77 | 2023-2024 | Flucelvax, Flucelvax Quadrivalent |
| Ironshore Pharmaceuticals INC. | $34.44 | 2024 | |
| Glaxosmithkline, LLC. | $31.30 | 2023-2024 | Bexsero, Pediarix, Rotarix |
| Noven Therapeutics, LLC | $30.38 | 2023 | Xelstrym, Secuado |
| Mayne Pharma Commercial LLC | $26.24 | 2024 | |
| Axsome Therapeutics, INC. | $22.89 | 2023 | Auvelity |
| Organon LLC | $21.04 | 2023 | Nexplanon |
| Astrazeneca Pharmaceuticals LP | $17.81 | 2024 | Flumist Quadrivalent |
| Almatica Pharma LLC | $16.11 | 2022 | |
| Phadia US INC. | $15.60 | 2024 | Immunocap |
| Bausch Health US, LLC | $15.37 | 2023 | Aplenzin, Wellbutrin |
| Biohaven Pharmaceuticals, INC. | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Cavanagh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.